Tradestie Institutional Equity Comparison Engine

SBC vs ACCL โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SBC Overall Edge

SBC Captures Institutional Edge (3โ€“0 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to SBC Medical Group Holdings Incorporated Common Stock (SBC) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, SBC trades at 13.6x Forward P/E with 37.3% operating margin (+13.4% YoY revenue) versus ACCL at N/M Forward P/E and 4.5% operating margin (+11.3% YoY). In options structure, SBC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ACCL sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner SBC
SBC 13.6x vs ACCL N/M Fwd P/E
Growth & Margin Winner SBC
Op Margin 37.3% vs 4.5% ยท YoY +13.4% vs +11.3%
Momentum & Technical Winner SBC
1Y +91.1% vs -42.4% ยท 52W Pos 79% vs 30%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
SBC NASDAQ
SBC Medical Group Holdings Incorporated Common Stock
Services-Offices & Clinics Of Doctors Of Medicine
$6.42
-12.65% 1D
Market Cap $549.2M
1M Return +24.42%
1Y Return +91.07%
Forward P/E 13.6x
Unified AI Score
47.6 / 100 HOLD
Tech 15.0 Fund 39.0 Flow 50.0 Mom 40.0
ACCL US Equity
ACCL
Institutional Equity
$2.36
-0.84% 1D
Market Cap $33.5M
1M Return -12.26%
1Y Return -42.44%
Forward P/E N/M
Unified AI Score
63.4 / 100 BUY
Tech 68.0 Fund 58.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SBC +91.07% ACCL -42.44% Spread: +134.74 pp (SBC Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SBC TTM Op. Margin: 37.3% ACCL TTM Op. Margin: 4.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SBC vs ACCL. Trailing 12-month operating profitability (SBC 37.3% vs ACCL 4.5%) and valuation multiples (SBC 13.6x vs ACCL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SBC (8) vs ACCL (2)
Institutional Metric SBC ACCL Criterion Row Winner
Market Capitalization Scale $549.2M $33.5M Larger Scale SBC
Trailing P/E Ratio Valuation 11.4x 120.0x Lower Multiple SBC
Forward P/E Ratio Valuation 13.6x N/M Lower Multiple SBC
Revenue Growth (YoY) Growth +13.4% +11.3% Higher Growth SBC
Operating Margin (TTM) Profitability 37.3% 4.5% Higher Margin SBC
Net Profit Margin Profitability 28.0% 5.5% Higher Margin SBC
Return on Equity (ROE) Capital Efficiency 18.9% 7.0% Higher ROE SBC
52-Week Range Position Momentum 79% ($3โ€“$7) 30% ($1โ€“$5) Stronger Trend SBC
Beta / 30D Volatility Risk Regime 0.65ฮฒ ยท 150% Vol -0.20ฮฒ ยท 60% Vol Lower Realized Risk ACCL
Unified Institutional Score Composite Signal 47.6 / 100 (HOLD) 63.4 / 100 (BUY) Higher Composite ACCL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SBC vs ACCL Buy Guide
SBC UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live SBC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ACCL UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ACCL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SBC nor ACCL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.